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Introduction
Several lines of evidence have shown that the non-competitive N-methyl-D-aspartate (NMDA) receptor
antagonist (R,S)-ketamine exerts rapid and long-lasting antidepressant effects in depressed patients, including those with treatment-resistant depression (Berman et al., 2000; Krystal et al., 2013; Zarate et al., 2006) . In addition to its rapid antidepressant effects, (R,S)-ketamine rapidly reduces suicidal ideation in depressed patients (DiazGranados et al., 2010) . Despite these ground-breaking findings, the routine use of (R,S)-ketamine in daily practice is prevented by some adverse effects, including psychotomimetic and dissociative symptoms after (R,S)-ketamine injection as well as the potential for abuse following chronic treatment with (R,S)-ketamine (Freedman, 2016; Newport et al., 2016) .
(R,S)-Ketamine is a racemic mixture containing the (R)-ketamine enantiomer and the (S)-ketamine enantiomer in equal parts. Of these, (S)-ketamine has been regarded as the active isomer because of its higher affinity for the NMDA receptor and greater anesthetic potency, compared with (R)-ketamine (Domino, 2010; Kohrs and Durieux, 1998) . Indeed, the intravenous injection of (S)-ketamine has been recently reported to exert rapid antidepressant effects in patients with treatment-resistant depression (Singh et al., 2016) , indicating that (S)-ketamine is the active isomer for antidepressant effects as well. Of note, the intranasal injection of (S)-ketamine is currently under development for the treatment of patients with treatment-resistant depression. However, similar to (R,S)-ketamine, (S)-ketamine can also lead to transient dissociative and psychotic symptoms in depressed patients (Singh et al., 2016) , although one case report has suggested that (S)-ketamine, unlike (R,S)-ketamine, does not induce psychotic symptoms (Paul et al., This article has not been copyedited and formatted. The final version may differ from this version. Recently, (R)-ketamine has been reported to exert more potent and longer-lasting antidepressant effects than (S)-ketamine in animal models, including the chronic social defeat stress model (Yang et al., 2015; Zanos et al., 2016; Zhang et al., 2014) . Very importantly, (R)-ketamine does not cause the adverse effects that are observed with (S)-ketamine treatment in rodents such as psychotomimetic behaviors, neurotoxicity and abuse potential (Yang et al., 2015) , even after repeated treatment (Yang et al., 2016) . In addition, (R)-ketamine, unlike (S)-ketamine, did not increase dopamine release in the striatum in monkeys , providing additional evidence for the lack of an association with psychotic symptoms and abuse liabilities. Based on these findings, (R)-ketamine may exert (R,S)-ketamine-like antidepressant effects but without adverse effects, potentially making it a more useful antidepressant than (R,S)-ketamine (Hashimoto, 2016a (Hashimoto, , 2016b .
However, evidence for the antidepressant effects of (R)-ketamine remains limited, and the usefulness of (R)-ketamine as an antidepressant has still not been established adequately. Moreover, some issues regarding the antidepressant effects of (R)-ketamine, such as its efficacy for treatment-resistant depression and the neural mechanisms underlying the antidepressant effects, remain to be solved. To address these issues, the antidepressant effects of (R)-ketamine must first be confirmed and then compared with those of (S)-ketamine in other animal models of depression, including one that is refractory to conventional antidepressants. Here, we compared the antidepressant effects of (R)-ketamine with those of (R,S)-ketamine and (S)-ketamine in rodent models of depression. Moreover, we also compared the drug levels of JPET #239228 7
Materials and Methods
Animals
Eight or nine-week-old male C57BL/6J mice (Charles River Laboratories, Yokohama, Japan), 5-week-old male ICR mice (Charles River Laboratories, Yokohama, Japan) and male Sprague-Dawley (SD) rats (4-weeks-old at the beginning of the experiments, 84-102 g; Charles River, Yokohama, Japan) were used for this study. After treatment with corticosterone (CORT) or vehicle for 21 consecutive days, 7-week-old rats (198-299 g) were used for the forced swimming test. The animals were maintained under controlled temperature (23.3 ± 3˚C) and humidity (50 % ± 20%) conditions with a 12-h light/dark cycle (lights on at 7:00 AM). Food and water were provided ad libitum except during the tests. All the experiments were conducted in accordance with the criteria of the Taisho Pharmaceutical Co., Ltd. Animal Care. Committee and met the Japanese Experimental Animal Research association standards, as defined in the Guidelines for Animal Experiments (1987) .
Drugs
Racemic ketamine ((R,S)-ketamine) (Veterinary Ketalar® 50; Sankyo Yell Pharmaceutical Co., Ltd., Tokyo, Japan) was diluted with saline. (R)-Ketamine hydrochloride and (S)-ketamine hydrochloride were prepared by the recrystallization of (R,S)-ketamine and D-(−)-tartaric acid (or L-(+)-tartaric acid), as described previously (Zhang et al., 2014) . The purity of these stereoisomers was determined using high-performance liquid chromatography (CHIRALPAK®IA, column size: 250 × 4.6 mm, mobile phase:
This article has not been copyedited and formatted. The final version may differ from this version. 
Forced swimming test in mice
Male C57BL/6J mice were used. The forced swimming test was performed using a previously reported method, with some modification (Fukumoto et al, 2016) . For the test, the mice were placed in a swim tank for 6 min on day 1 to induce a state of helplessness, then placed back in the swim tank for 6 min on day 2 to measure the immobility time. The swimming sessions were conducted by placing the mice in cylinders (24 cm height × 17 cm diameter) containing water (25 ± 1 ºC) up to a height of 13 cm, so that the mice could not support themselves by touching the bottom of the tank with their paws. The forced swimming test was conducted between 8:00 AM and 17:00 PM. The water in the cylinders was changed after every trial.
The test sessions were videotaped from the front of the cylinders for later scoring by a scorer. The total duration of immobility during a 6-min test session was measured by an observer who was blinded to the treatment conditions. Immobility was defined as floating in the water without struggling and only making 
Tail suspension test in mice
Male ICR mice were used. The tail suspension test was performed according to a previously described method (Steru et al., 1985) , with some modifications. Mice were suspended by the tail from a metal rod using adhesive tape. The rod was fixed 45 cm above the surface of a table in a sound-isolated room. The mouse was positioned at least 15 cm away from the nearest object. The test session was recorded for 6 min, and the immobility time was determined by an observer who was blinded to the treatment conditions. The mice were considered immobile only when they hung passively and were completely motionless.
(R)-Ketamine, (S)-ketamine or (R,S)-ketamine was administered i.p. at 30 min, 24 h or 48 h prior to the test.
Separate cohorts of mice were used to test at each time point. Desipramine, used as a positive control, was administered i.p. at 30 min prior to the test. All the drugs were injected at a volume of 10 mL/kg body weight.
Repeated CORT treatment model of rats
The forced swimming test using repeated CORT treated rats was performed according to a previously reported method (Iijima et al., 2010) . Male SD rats were injected daily with CORT (20 mg/kg) or the vehicle alone for 21 days. All the injections were delivered subcutaneously (s.c.) once per day between 7:00 AM and 11:00 AM for 21 consecutive days.
The forced swimming test was performed 48 h after the final injection of CORT. The forced swimming test was performed according to a previously reported method (Johnson et al., 2006) . In the present study, the rats were tested in the swim tank only once, as we sought to assess helplessness induced by prior exposure to CORT injections, rather than prior exposure to the swim task itself. The swimming sessions were conducted by placing the rats in cylinders containing water at a temperature of 25°C and a depth of 30 cm, so that the rats could not support themselves by touching the bottom with their feet. The forced swimming test was conducted for 10 min between 9:00 AM and 13:00 PM. The water in the cylinders was changed after every trial. The test sessions were videotaped from the front of the cylinders for later scoring by an observer who was blinded to the treatment conditions. Immobility was regarded as floating in the water without struggling and only making movements necessary to keep its head above the water.
(R)-Ketamine, (S)-ketamine or (R,S)-ketamine was administered i.p. twice at 24 h and 30 min or once at 24 h prior to the forced swimming test. The effect of NBQX was examined in cases treated with (R)-ketamine once at 24 h prior to the test; NBQX was administered s.c. at 5 min prior to the i.p. administration of (R)-ketamine. All the drugs were injected at a volume of 2 mL/kg body weight.
Measurement of spontaneous locomotor activity in mice and rats
Spontaneous locomotor activity was determined as previously reported (Yang et al., 2015) . Male SD rats or male C57BL/6J mice were used. The animals were housed individually in transparent acrylic cages (for rats, 47 x 28.5 x 29.5 cm; for mice, 30 cm in diameter, 30 cm in height), and (R)-ketamine or (S)-ketamine was injected i.p. after habituation (60 min) to the cage. After the injection, spontaneous locomotor activity was immediately recorded every 10 min for 60 min using a SCANET apparatus (Neuroscience Inc., Tokyo, Japan) placed in a soundproof box.
Determination of (R)-ketamine and (S)-ketamine in plasma, brain and CSF in mice and rats
Sample collection and preparation ice-cold saline and then homogenized with 4 volumes of distilled water to prepare a brain homogenate specimen. The CSF (mouse: pooled from 3 animals, rat: individual) was diluted with saline four times (mice) or twice (rats) to prepare a CSF specimen. These biological specimens were stored at -30°C until bioanalysis.
Bioanalysis
A 50-µL aliquot of the biological specimen except for mouse plasma and CSF was mixed with 100 µL of acetonitrile/methanol (9:1, v/v) containing 2 H 4 -norketamine (Sigma-Aldrich, St. Louis, MO) as an internal standard (I.S.). The mouse plasma and CSF specimens at volumes of 5 µL and 10 µL, respectively, were subjected to the above-mentioned pretreatment. Each sample was stirred for approximately 30 s using a vortex mixer and centrifuged (preset value, 3700 ×g, 10 min). A 0.5-µL aliquot of the resulting supernatant was subjected to an enantioselective LC-MS/MS analysis. The analytical system was constructed using a Shimadzu LC-30AD high-performance liquid chromatography system (Shimadzu, Tokyo, Japan) and a TripleQuad5500 mass spectrometer (AB SCIEX, Foster City, CA). The MS data were acquired and processed using Analyst version 1.6 software (AB SCIEX, Foster City, CA). Chromatographic separation was performed at 25°C on a CHIRALPAK AS-3R analytical column (4.6 mm i. 13 ng/mL (rats); the LLOQ in the brain was 0.5 ng/g for both species; the LLOQ in CSF was 2 ng/mL (mice) or 0.2 ng/mL (rats).
Statistical analysis
All the data were analyzed using a one-way analysis of variance. Subsequent comparisons between the vehicle and treatment groups were performed using the Student's t-test or the Dunnett's test. All the data were analyzed using SAS System Version 9.2 (SAS Institute Japan Ltd., Tokyo, Japan).
Results
Antidepressant effects of (R)-ketamine and (S)-ketamine in the mouse forced swimming test
Both ( (Fig. 2d) . (Fig. 3a) . to the test did not affect the CORT treatment-increased immobility time (Fig. 3b) . The effect of (R)-ketamine on CORT treatment-increased immobility was significantly prevented by pretreatment with NBQX (10 mg/kg) [F(3, 28) = 8.92, P < 0.01] (Fig. 4a) , while NBQX (10 mg/kg) per se did not affect CORT treatment increased immobility [F(1, 14) = 1.51, P = 0.24] (Fig. 4b) .
Effects of (R)-ketamine, (S)-ketamine and (R,S)-ketamine administered at
Effect of (R)-ketamine and (S)-ketamine on locomotor activity in mice and rats
Both ( (Table 1) .
Determination of (R)-ketamine and (S)-ketamine in plasma, brain and CSF in mice and rats
The exposure levels of (R)-ketamine or (S)-ketamine in the rodent plasma, brain and CSF were determined after a single i.p. administration of each ketamine enantiomer to mice (10 or 30 mg/kg) and rats No significant differences in the concentrations of (R)-ketamine and (S)-ketamine were observed in either the brain or the CSF (Table 2) , as well as in the plasma concentration time profiles. At 0.5 h post-dose, the brain and CSF levels of both ketamine enantiomers were measureable in all the animals. The brain specimens exhibited higher levels than the plasma samples, with brain-to-plasma concentration ratios of 1.3 -2.6 (mice) and 1.7 -2.2 (rats), while the CSF levels were lower than the plasma levels, with CSF-to-plasma concentration ratios of 0.2 -0.5 (mice) and 0.3 -0.4 (rats). At 24 h post-dose, both the (R)-ketamine and (S)-ketamine concentrations in the tissues were below the LLOQ in both species except for in mouse brain after a dose of 30 mg/kg, in which only (S)-ketamine was measurable at a trace levels near the LLOQ.
Discussion
In the present study, we provided additional evidence that (R)-ketamine exhibited longer-lasting antidepressant effects than (S)-ketamine in rodent models of depression. In addition, we, for the first time, demonstrated that (R)-ketamine reversed depressive-like behavior in an animal model that is refractory to conventional antidepressants, while (S)-ketamine did not show a sustained effect in this model. Moreover, we also demonstrated that the effect of (R)-ketamine in the treatment-resistant model was mediated through the stimulation of the -amino-3-hydroxy-5-methylisoxazole-4-propionate (AMPA) receptor. Finally, we confirmed differential antidepressant effects between (R)-ketamine and (S)-ketamine that cannot be ascribed to differences in their pharmacokinetic profiles.
In two despair models in mice, the forced swimming test and the tail suspension test, both (R)-ketamine and (S)-ketamine reduced the immobility time at 30 min after administration (acute effects), while (S)-ketamine showed effects at a lower dose (10 mg/kg, i.p.) than (R)-ketamine. However, even at 10 mg/kg (i.p.), (S)-ketamine and (R)-ketamine transiently increased locomotor activity in mice after acute administration, which may have large effects on the outcomes in these animal models. Therefore, the acute effects of both compounds may be partly ascribed to increased locomotor activity, and we cannot conclude that (S)-ketamine had more potent acute effects than (R)-ketamine in these despair models. It should be noted that (R)-ketamine has been reported to show acute antidepressant effects at lower doses than (S)-ketamine in other animal models (Zanos et al., 2016) , suggesting that the potency of the acute effects may depend on the test that is used or the testing conditions. Moreover, we obtained results indicating that the exposure levels of both compounds in the brain and CSF were approximately the same after administration. Thus, the difference in potency between (R)-ketamine and (S)-ketamine cannot be ascribed to differences in their pharmacokinetic profiles.
In addition to the acute effects, both (R)-ketamine and (S)-ketamine showed sustained antidepressant effects at 24 h after administration in these models. The pharmacokinetic results showed that both compounds no longer existed in the brain or CSF at 24 h after administration. Therefore, secondary changes, presumably adaptive synaptic plasticity, induced by the compound rather than the direct actions of the compound during the test may have been involved in the sustained antidepressant effects. Moreover, in the tail suspension test, we obtained the result that (R)-ketamine still showed antidepressant effects at 48 h after administration, as did (R,S)-ketamine, while (S)-ketamine no longer showed the effects. Therefore, (R)-ketamine may have longer-lasting antidepressant effects in the animal model than (S)-ketamine, which is consistent with previously reported results (Yang et al., 2015; Zanos et al., 2016; Zhang et al., 2014) .
Since (R)-ketamine has a lower affinity at the NMDA receptor than (S)-ketamine, this result raises the possibility that mechanisms other than NMDA receptor blockade may be involved in the longer-lasting antidepressant effects of (R)-ketamine.
The repeated administration of CORT induces depressive-like behavior in rodents, such as increased immobility during the forced swimming test; this behavior is not improved by acute treatment with
This article has not been copyedited and formatted. The final version may differ from this version. conventional antidepressants (Iijima et al., 2010) . Thus, this model may be regarded as a model of depression refractory to current medications, although there is a report showing that chronic treatment with conventional antidepressants reversed the repeated CORT treatment-induced anhedonia (Gourley and Taylor, 2009) . We observed that (R,S)-ketamine reversed the depressive-like behavior in this model (Koike et al., 2013) , reflecting the clinical finding that (R,S)-ketamine is effective for patients with treatment-resistant depression (Zarate et al., 2006) . In the present study, both ( antidepressant effects of (R)-ketamine and (S)-ketamine might not be due to differences in the pharmacokinetic profiles of the two compounds, and secondary changes, rather than direct actions, induced by (R)-ketamine may be involved in the sustained effects. The present result contrasts that of a recent report indicating that (S)-ketamine exerted long-lasting anti-anhedonic effects for 32 days in CORT treated rats (Soumier et al., 2016) . However, in their study, (S)-ketamine was injected before repeated CORT treatment, while both (R)-ketamine and (S)-ketamine were injected after CORT treatment in the present study.
Therefore, the present study investigated only the therapeutic effects, and not the prophylactic effects.
In the present study, the sustained antidepressant effect of (R)-ketamine was attenuated by pretreatment with NBQX, an AMPA receptor antagonist. Therefore, AMPA receptor stimulation is involved in the sustained antidepressant effects of (R)-ketamine, which is in line with previous findings in a chronic social defeat stress model of mice (Yang et al., 2015) . Given that the sustained antidepressant effects of (R,S)-ketamine and the increase in the synthesis of synaptic proteins induced by (R,S)-ketamine are mediated through AMPA receptor stimulation (Koike et al., 2011 (Koike et al., , 2014 Li et al., 2010) and that AMPA receptor potentiation has been reported to have a pivotal role to exert antidepressant effects (Alt et al., 2006) , it is plausible to speculate that (R)-ketamine may exert the sustained antidepressant effects through changes in synaptic plasticity, which are mediated via the AMPA receptor.
Precise mechanisms explaining the differences in the antidepressant effects of (R)-ketamine and (S)-ketamine remain to be elucidated. Although a metabolite of (R)-ketamine, (2R,6R)-hydroxynorketamine, has recently been reported to be responsible for the long-lasting antidepressant effects of (R,S)-ketamine (Zanos et al., 2016) , (R)-ketamine itself may be responsible for the long-lasting antidepressant effects, because the local injection of (R)-ketamine into brain nuclei reportedly exerts sustained antidepressant effects (Shirayama et al., 2016) and we recently reported that antidepressant effects of (R)-ketamine is much greater than those of (2R,6R)-hydroxynorketamine (Yang et al., in press ). In either case, because both (R)-ketamine and its metabolite have a lower affinity for the NMDA receptor than (S)-ketamine (Kohrs and Durieux, 1998; Zanos et al., 2016) , mechanisms other than the NMDA receptor blockade may be involved in the antidepressant effects of (R)-ketamine. In the present study, while both (R)-ketamine and (S)-ketamine exerted long-lasting antidepressant effects even when they were no longer present in the brain and CSF, only (R)-ketamine exerted sustained antidepressant effects in the repeated CORT treatment model in which reduced synaptic plasticity has been reported (Pazini et al., 2016) . Therefore, the difference in the potency of the effects on synaptic plasticity may be responsible for the differences in the sustained antidepressant effects. This assumption may be underpinned by the report that (R)-ketamine reversed a social defeat stress-induced reduction in dendritic spine density and brain-derived neurotrophic factor levels more robustly than (S)-ketamine on the eighth day after the single administration (Yang et al., 2015) .
One of the limitations of the present study is that we did not address safety issues regarding (R)-ketamine.
Indeed, when we investigated the effects of (R)-ketamine and (S)-ketamine on locomotor activity in mice, increased locomotor activity was observed at doses of both 10 and 30 mg/kg, i.p. Although increased locomotor activity does not necessarily reflect psychotomimetic liability in human, this finding markedly contrasts the previous finding that (R)-ketamine (5, 10, 20 mg/kg, i.p.) did not affect locomotor activity, while (S)-ketamine (10 and 20 mg/kg, i.p.) markedly increased locomotor activity in mice (Yang et al., 2015) . In both experiments, the same strain of mice and the same time schedule were used. Although the reason for this discrepancy is not known, differences in the experimental apparatuses that were used or in specific treatment conditions might have led to the different outcomes. Further studies are required to assess the safety profiles of (R)-ketamine, including the abuse potential and neurotoxicity. Another limitation of the present study is that long-lasting antidepressant effects of (R,S)-ketamine in rodent models are not universally observed (Bechtholt-Gompf et al., 2011; Popik et al., 2008) . Therefore, data obtained in animal models have to be confirmed in clinical studies.
In conclusion, we confirmed that (R)-ketamine exerted longer-lasting antidepressant effects than Data are presented as the mean ± SD of 3 animals.
The LLOQ in plasma was 1 ng/mL (mice) or 0.1 ng/mL (rats); the LLOQ in brain was 0.5 ng/g for both spices; the LLOQ in cerebrospinal fluid was 2 ng/mL (mice) or 0.2 ng/mL (rats). 
